Annual Total Long Term Liabilities
$166.10 M
+$4.64 M+2.88%
December 31, 2023
Summary
- As of February 7, 2025, PHAR annual total long term liabilities is $166.10 million, with the most recent change of +$4.64 million (+2.88%) on December 31, 2023.
- During the last 3 years, PHAR annual total long term liabilities has risen by +$7.94 million (+5.02%).
- PHAR annual total long term liabilities is now at all-time high.
Performance
PHAR Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$119.88 M
+$4.83 M+4.20%
September 30, 2024
Summary
- As of February 7, 2025, PHAR quarterly total long term liabilities is $119.88 million, with the most recent change of +$4.83 million (+4.20%) on September 30, 2024.
- Over the past year, PHAR quarterly long term liabilities has increased by +$91.44 million (+321.56%).
- PHAR quarterly long term liabilities is now -30.34% below its all-time high of $172.11 million, reached on September 30, 2020.
Performance
PHAR Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
PHAR Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2.9% | +321.6% |
| 3 y3 years | +5.0% | -23.9% |
| 5 y5 years | +107.0% | +172.3% |
PHAR Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +5.4% | -27.8% | +321.6% |
| 5 y | 5-year | at high | +584.3% | -30.3% | +393.9% |
| alltime | all time | at high | >+9999.0% | -30.3% | +1300.3% |
Pharming Group NV Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $119.88 M(+4.2%) |
| Jun 2024 | - | $115.05 M(+304.6%) |
| Mar 2024 | - | $28.44 M(-82.9%) |
| Dec 2023 | $166.10 M(+2.9%) | $166.10 M(+4.8%) |
| Sep 2023 | - | $158.47 M(-3.7%) |
| Jun 2023 | - | $164.48 M(-0.1%) |
| Mar 2023 | - | $164.65 M(+2.0%) |
| Dec 2022 | $161.46 M(+2.4%) | $161.46 M(+19.3%) |
| Sep 2022 | - | $135.38 M(-6.7%) |
| Jun 2022 | - | $145.03 M(-5.6%) |
| Mar 2022 | - | $153.63 M(-2.5%) |
| Dec 2021 | $157.63 M(-0.3%) | $157.63 M(-1.9%) |
| Sep 2021 | - | $160.66 M(-3.2%) |
| Jun 2021 | - | $166.03 M(+11.6%) |
| Mar 2021 | - | $148.83 M(-5.9%) |
| Dec 2020 | $158.17 M(+551.6%) | $158.17 M(-8.1%) |
| Sep 2020 | - | $172.11 M(+5.1%) |
| Jun 2020 | - | $163.81 M(+3.2%) |
| Mar 2020 | - | $158.73 M(+553.9%) |
| Dec 2019 | $24.27 M(-69.7%) | $24.27 M(-44.9%) |
| Sep 2019 | - | $44.02 M(-37.9%) |
| Jun 2019 | - | $70.87 M(-7.5%) |
| Mar 2019 | - | $76.62 M(-4.5%) |
| Dec 2018 | $80.22 M(-25.1%) | $80.22 M(+18.5%) |
| Sep 2018 | - | $67.69 M(-23.3%) |
| Jun 2018 | - | $88.25 M(-10.5%) |
| Mar 2018 | - | $98.57 M(-8.0%) |
| Dec 2017 | $107.18 M(+112.6%) | $107.18 M(+17.6%) |
| Sep 2017 | - | $91.13 M(-7.1%) |
| Jun 2017 | - | $98.08 M(+124.4%) |
| Mar 2017 | - | $43.71 M(-13.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $50.42 M(+126.5%) | $50.42 M(+188.3%) |
| Sep 2016 | - | $17.49 M(-7.8%) |
| Jun 2016 | - | $18.96 M(-8.9%) |
| Mar 2016 | - | $20.82 M(-6.5%) |
| Dec 2015 | $22.26 M(+66.4%) | $22.26 M(-12.7%) |
| Sep 2015 | - | $25.51 M(+132.0%) |
| Jun 2015 | - | $11.00 M(-2.3%) |
| Mar 2015 | - | $11.25 M(-15.9%) |
| Dec 2014 | $13.38 M(-28.1%) | $13.38 M(-9.7%) |
| Sep 2014 | - | $14.81 M(-12.0%) |
| Jun 2014 | - | $16.84 M(-4.7%) |
| Mar 2014 | - | $17.67 M(-5.0%) |
| Dec 2013 | $18.60 M(-9.4%) | $18.60 M(-6.3%) |
| Sep 2013 | - | $19.86 M(+5.7%) |
| Jun 2013 | - | $18.79 M(-1.5%) |
| Mar 2013 | - | $19.08 M(-7.1%) |
| Dec 2012 | $20.54 M(-10.7%) | $20.54 M(-3.2%) |
| Sep 2012 | - | $21.21 M(-6.8%) |
| Mar 2012 | - | $22.76 M(-1.0%) |
| Dec 2011 | $23.00 M(-1.2%) | $23.00 M(-8.0%) |
| Sep 2011 | - | $25.01 M(-9.2%) |
| Jun 2011 | - | $27.54 M(+14.7%) |
| Mar 2011 | - | $24.00 M(+3.1%) |
| Dec 2010 | $23.28 M(+157.9%) | $23.28 M(-3.7%) |
| Sep 2010 | - | $24.18 M(+114.3%) |
| Jun 2010 | - | $11.28 M(+31.8%) |
| Mar 2010 | - | $8.56 M(-5.2%) |
| Dec 2009 | $9.03 M(-84.6%) | $9.03 M |
| Dec 2008 | $58.49 M(-33.0%) | - |
| Dec 2007 | $87.31 M(+230.0%) | - |
| Dec 2006 | $26.45 M(>+9900.0%) | - |
| Dec 2005 | $165.80 K | - |
FAQ
- What is Pharming Group NV annual total long term liabilities?
- What is the all time high annual total long term liabilities for Pharming Group NV?
- What is Pharming Group NV annual total long term liabilities year-on-year change?
- What is Pharming Group NV quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Pharming Group NV?
- What is Pharming Group NV quarterly long term liabilities year-on-year change?
What is Pharming Group NV annual total long term liabilities?
The current annual total long term liabilities of PHAR is $166.10 M
What is the all time high annual total long term liabilities for Pharming Group NV?
Pharming Group NV all-time high annual total long term liabilities is $166.10 M
What is Pharming Group NV annual total long term liabilities year-on-year change?
Over the past year, PHAR annual total long term liabilities has changed by +$4.64 M (+2.88%)
What is Pharming Group NV quarterly total long term liabilities?
The current quarterly long term liabilities of PHAR is $119.88 M
What is the all time high quarterly long term liabilities for Pharming Group NV?
Pharming Group NV all-time high quarterly total long term liabilities is $172.11 M
What is Pharming Group NV quarterly long term liabilities year-on-year change?
Over the past year, PHAR quarterly total long term liabilities has changed by +$91.44 M (+321.56%)